Mechanisms of Functional Recovery After Partial Nerve Injury

部分神经损伤后功能恢复的机制

基本信息

  • 批准号:
    8426003
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-04-01 至 2016-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Nerve injury is a common cause of permanent neurological disability in the combat military and veterans. It is well-known that victims of nerve injury follow highly variable clinical trajectories. Some patients make a full recovery, yet a very large number fail to regain normal function. Unfortunately, there are no treatments that improve chances to restore neurological function. A great deal of work has focused on encouraging axonal regrowth after nerve injury. In contrast, very little is known about how the nervous system functionally compensates after nerve damage; functional compensation therefore represents an underappreciated pathway to reducing disability from nerve injuries. We propose studies in animal models to demonstrate the efficacy of hormone receptor modulation for enhancing functional recovery without axonal growth. In preliminary work, we demonstrate a model system to study functional neuronal recovery without axon regeneration. Normally, the bilateral superior cervical ganglia (SCG) both innervate the pineal gland to stimulate nightly melatonin synthesis. In Fischer 344 (F344) rats, when we remove one SCG (1xSCGx), melatonin falls to 50% of basal levels; the day after this drop, melatonin spontaneously returns to 100% of basal levels, indicating functional recovery of the neural circuit occurs in the absence of axon regrowth. In Brown Norway (BN) rats, which carry a gain of function mutation in the mineralocorticoid receptor (MR), melatonin levels fall immediately and fail to make improvements. When BN rats are treated with corticosteroids or with antagonists of MR, rats make a rapid and permanent recovery in melatonin synthesis. These studies indicate that a neural circuit can spontaneously recover normal function without axon growth, and that steroids that act on MR or the glucocorticoid receptor (GR) are capable of enhancing functional neurological recovery. In this proposal, we will test the core hypothesis that MR antagonists and GR agonists promote function recovery when administered during specific periods after neuronal injury; we further hypothesize that MR and GR modulation after neuronal injury modifies the inflammatory response that is required for optimal compensation to neurological injury. The following specific aims will be tested. In Aim 1, we will test the time course of administration of MR antagonists for enhancing neurological recovery after partial nerve injury. In Aim 2, we will test the time course of administration of GR agonists for enhancing neurological recovery after partial nerve injury. Finally, in Aim 3, we will test the role of inflammatory cytokines on functional recovery from partial nerve injury. We hypothesize that a cascade of specific cytokines results from denervation of target tissue and that protective cytokine responses are driven by steroid hormone regulated transcription and correlate with long term functional recovery. These experiments promise to define time windows for potential clinical treatment of nerve injury and will identify molecular markers and signaling pathways that promote functional recovery after peripheral nerve injury.
描述(由申请人提供): 在战斗军人和退伍军人中,神经损伤是导致永久性神经残疾的常见原因。众所周知,神经损伤的受害者遵循高度不同的临床轨迹。一些患者完全康复了,但很大一部分患者未能恢复正常功能。不幸的是,没有任何治疗方法可以提高恢复神经功能的机会。大量的工作集中在促进神经损伤后轴突的再生。相比之下,人们对神经系统在神经损伤后如何进行功能补偿知之甚少;因此,功能补偿是减少神经损伤所致残疾的一条被低估的途径。我们建议在动物模型中进行研究,以证明激素受体调节在促进功能恢复方面的有效性,而不需要轴突生长。在前期工作中,我们展示了一个研究无轴突再生的功能性神经元恢复的模型系统。正常情况下,双侧颈上神经节(SCG)均支配松果体以刺激夜间褪黑激素的合成。在Fischer 344(F344)大鼠中,当我们移除一个SCG(1xSCGx)时,褪黑素下降到基础水平的50%;在这种下降之后的第二天,褪黑素自发恢复到基础水平的100%,这表明在没有轴突再生的情况下,神经回路的功能恢复发生。在携带盐皮质激素受体(MR)功能突变的棕色挪威(BN)大鼠中,褪黑激素水平立即下降,无法改善。当BN大鼠接受皮质类固醇或MR拮抗剂治疗时,大鼠褪黑素的合成迅速而永久地恢复。这些研究表明,神经回路可以在没有轴突生长的情况下自发恢复正常功能,作用于MR或糖皮质激素受体(GR)的类固醇能够促进神经功能的恢复。在这个方案中,我们将检验MR拮抗剂和GR激动剂在神经元损伤后的特定时间内使用时促进功能恢复的核心假设;我们进一步假设神经元损伤后MR和GR的调节改变了对神经损伤的最佳补偿所需的炎症反应。将测试以下具体目标。在目标1中,我们将测试MR拮抗剂用于促进部分神经损伤后神经恢复的时间进程。在目标2中,我们将测试GR激动剂用于促进部分神经损伤后神经恢复的时间进程。最后,在目标3中,我们将测试炎性细胞因子在部分神经损伤后功能恢复中的作用。我们假设特定细胞因子的级联反应是靶组织失神经的结果,保护性细胞因子反应是由类固醇激素调节的转录驱动的,并与长期功能恢复相关。这些实验有望为神经损伤的潜在临床治疗确定时间窗口,并将识别促进周围神经损伤后功能恢复的分子标志物和信号通路。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael M Wang其他文献

Blood‐brain barrier models derived from individual patients: a new frontier
来自个体患者的血脑屏障模型:一个新领域
  • DOI:
    10.1111/jnc.13961
  • 发表时间:
    2017
  • 期刊:
  • 影响因子:
    4.7
  • 作者:
    J. Xiang;A. Andjelkovic;Michael M Wang;R. Keep
  • 通讯作者:
    R. Keep

Michael M Wang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michael M Wang', 18)}}的其他基金

NOTCH3 N-terminal fragmentation in cerebral small vessel disease
脑小血管疾病中的 NOTCH3 N 末端断裂
  • 批准号:
    9919009
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
NOTCH3 N-terminal fragmentation in cerebral small vessel disease
脑小血管疾病中的 NOTCH3 N 末端断裂
  • 批准号:
    10397084
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
Pathological protein generation in cerebral small vessel disease
脑小血管疾病中的病理蛋白生成
  • 批准号:
    9347154
  • 财政年份:
    2017
  • 资助金额:
    --
  • 项目类别:
Pathological protein generation in cerebral small vessel disease
脑小血管疾病中的病理蛋白生成
  • 批准号:
    9898311
  • 财政年份:
    2017
  • 资助金额:
    --
  • 项目类别:
Transformation of NOTCH3 protein in cerebral small vessel disease
NOTCH3蛋白在脑小血管疾病中的转化
  • 批准号:
    10047287
  • 财政年份:
    2017
  • 资助金额:
    --
  • 项目类别:
Advanced conformational changes in NOTCH3 and cerebrovascular disease severity
NOTCH3 的高级构象变化和脑血管疾病的严重程度
  • 批准号:
    10257491
  • 财政年份:
    2017
  • 资助金额:
    --
  • 项目类别:
Advanced conformational changes in NOTCH3 and cerebrovascular disease severity
NOTCH3 的高级构象变化和脑血管疾病的严重程度
  • 批准号:
    10513318
  • 财政年份:
    2017
  • 资助金额:
    --
  • 项目类别:
Identification and functional analysis of novel human-specific small vessel disease proteins
新型人类特异性小血管疾病蛋白的鉴定和功能分析
  • 批准号:
    9356592
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:
Mechanisms of Functional Recovery After Partial Nerve Injury
部分神经损伤后功能恢复的机制
  • 批准号:
    8201516
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Mechanisms of Functional Recovery After Partial Nerve Injury
部分神经损伤后功能恢复的机制
  • 批准号:
    8838168
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
  • 批准号:
    10534864
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了